Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Generation of SARS-CoV-2 escape mutations by monoclonal antibody therapy.

Ragonnet-Cronin M. et al, (2023), Nat Commun, 14

Isolation of a pair of potent broadly neutralizing mAb binding to RBD and SD1 domains of SARS-CoV-2

Stuart D. et al, (2023)

Humoral responses against SARS-CoV-2 Omicron BA.2.11, BA.2.12.1 and BA.2.13 from vaccine and BA.1 serum.

Huo J. et al, (2022), Cell discovery, 8

Genome-first detection of emerging resistance to novel therapeutic agents for SARS-CoV-2

Ragonnet-Cronin M. et al, (2022)

Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum

Tuekprakhon A. et al, (2022), Cell, 185, 2422 - 2433.e13

Potent cross-reactive antibodies following Omicron breakthrough in vaccinees

Nutalai R. et al, (2022), Cell, 185, 2116 - 2131.e18

SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses

Dejnirattisai W. et al, (2022), Cell, 185, 467 - 484.e15

Structures and therapeutic potential of anti-RBD human monoclonal antibodies against SARS-CoV-2

Huang K-YA. et al, (2022), Theranostics, 12, 1 - 17

The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants.

Liu C. et al, (2022), Cell host & microbe, 30, 53 - 68.e12

Antibody evasion by the P.1 strain of SARS-CoV-2

Dejnirattisai W. et al, (2021), Cell, 184, 2939 - 2954.e9

Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera

Zhou D. et al, (2021), Cell, 184, 2348 - 2361.e6

Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera

Supasa P. et al, (2021), Cell, 184, 2201 - 2211.e7

Author Correction: Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2

Huo J. et al, (2021), Nature Structural & Molecular Biology, 28, 326 - 326

Hand-foot-and-mouth disease virus receptor KREMEN1 binds the canyon of Coxsackie Virus A10

Zhao Y. et al, (2020), Nature Communications, 11

Author Correction: Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2

Huo J. et al, (2020), Nature Structural & Molecular Biology, 27, 1094 - 1094

Structural and functional analysis of protective antibodies targeting the threefold plateau of enterovirus 71.

Huang K-YA. et al, (2020), Nature communications, 11

Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient

Zhou D. et al, (2020), Nature Structural & Molecular Biology, 27, 950 - 958

Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike

Huo J. et al, (2020), Cell Host & Microbe, 28, 445 - 454.e6

Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike

Huo J. et al, (2020), Cell Host & Microbe, 28, 497 - 497

Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2

Huo J. et al, (2020), Nature Structural & Molecular Biology, 27, 846 - 854

Load More

Include forthcoming?